CompletedNot applicableNCT02080650
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
Studying Small cell carcinoma of the bladder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Duke University
- Principal Investigator
- Andrew J Armstrong, MDDuke University
- Intervention
- Mesenchymal-marker based ferrofluid (c-MET)(device)
- Enrollment
- 62 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2016
Study locations (1)
- Duke University Medical Center, Durham, North Carolina, United States
Collaborators
Prostate Cancer Foundation · Janssen Diagnostics, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02080650 on ClinicalTrials.govOther trials for Small cell carcinoma of the bladder
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07218003A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Rondo Therapeutics
- RECRUITINGPHASE2NCT06161532Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06228066Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT06257264A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsBeiGene
- RECRUITINGPHASE2NCT05312671Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT05621837Quantifying Systemic Immunosuppression to Personalize Cancer TherapyFondazione IRCCS Istituto Nazionale dei Tumori, Milano
- ACTIVE NOT RECRUITINGNCT05219734MRD Assay Evaluates Recurrence and Response Via a Tumor Informed AssessmentInvitae Corporation
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04644068Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesAstraZeneca